Dr Giralt spoke about the role of transplant and began by stating "There really are multiple [types of ] myelomas...should they all be treated the same?" He noted that while SCT's still show a benefit when compared with non-SCT regimens such as Melpalan-Prednisome-Revlimid (MPR), after 2yrs (OS 90% vs 87%), it's close. And it's why a new trial between France and the US is accruing patients who will compare RVD followed by a transplant or not to help answer questions about transplant benefits.
It's always a pleasure for me to listen to Dr Anderson, who always is so positive about the progress being made in treating MM. I counted between 20-25 new drugs beyond Carfilzomib and Pomolidomide which he spoke about enthusiastically. And these are drugs that are complementing each other at the cellular level. For example, did you know that as good as Velcade is, it also enhances AKt expression (this is bad)? So combine it with an AKt inhibitor such as Perifosine and you get a synergistic benefit. He ended by saying that genomic profiling of patients over time will be necessary for personalized medicine because changes occur..."the best is yet to come". If you ever get a chance to see or listen to Dr Anderson, please do so...I'm sure the IMF will interview him for their ASH updates.
Speaking of the IMF, this afternoon I attended a presentation on how we individuals can get more involved in legislative issues that benefit us. It's easy...just go to their website's Action Center to get involved and make a difference! And tonight I attended an IMF Media Reception followed by a Grants Award Reception where the IMF announces grant awards to various researchers. It was very exciting seeing young researchers investigating myeloma treatments which may make a difference in our future lives.
Here's to young, creative, brilliant minds...